CONSTELLA 145 MCG — DIN 02417162
LINACLOTIDE : 145 MCG · ABBVIE CORPORATION · CAPSULE · wholesale supply in Canada
Health Canada status: MARKETED
What is CONSTELLA?
CONSTELLA 145 MCG contains LINACLOTIDE : 145 MCG. It is listed in the Health Canada Drug Product Database under DIN 02417162, held by ABBVIE CORPORATION, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 11-Dec-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CONSTELLA used for?
CONSTELLA (linaclotide capsules) is indicated for the treatment of: • irritable bowel syndrome with constipation (IBS-C) in adults. • chronic idiopathic constipation (CIC) in adults. • functional constipation (FC) in pediatric patients 6 to 17 years of age.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Linaclotide cost around the world?
Linaclotide is listed on 2 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Saudi Arabia publishes a public. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 1 | 2 | SAR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 1 | 1 | EUR███.██ |
3 pack listings across 2 brand entries and 2 price bases, refreshed 03 Sep 2026. Ranges span every Linaclotide pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Linaclotide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Linaclotide — 3 DINs, of which 3 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ABBVIE CORPORATION | 3 | 3 | CONSTELLA | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 145 MCG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
| Pack configuration (monograph) | CONSTELLA contains linaclotide-coated beads in hard gelatin capsules. CONSTELLA is available as 72, 145 or 290 mcg capsules for oral administration. • 72 mcg Capsules: Each 72 mcg white to off-white, opaque, hard, gelatin capsule is imprinted with grey imprint "FL 72". Available in bottles of 30 capsules. • 145 mcg Capsules: Each 145 mcg white to off-white, opaque, hard, gelatin capsule is imprinted with a grey imprint “FL 145.” Available in bottles of 30 capsules. • 290 mcg Capsules: Each 290 mcg white to off-white, opaque, hard, gelatin capsule is imprinted with a grey imprint “FL 290.” Available in bottles of 30 capsules. |
| Storage | Store at room temperature (15 to 25°C). Keep CONSTELLA in the original container. Do not subdivide or repackage. Protect from moisture. Do not remove desiccant from the container. Keep bottles tightly closed in a dry place. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Linaclotide |
|---|---|
| ATC code | A06AX04 |
| AHFS class | 56:92.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02417162 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2417162 |
| Brand name | CONSTELLA |
| Generic / active ingredient | LINACLOTIDE : 145 MCG |
| Market authorization holder | ABBVIE CORPORATION |
| Health Canada schedule | Prescription |
| ATC code | A06AX04 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A06AX |
| Current status | MARKETED |
| Status date | 11-Dec-2023 |
| Original market date | 2014-04-29 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
CONSTELLA capsules should be taken orally once daily on an empty stomach, at least 30 minutes before a meal. The capsules should be swallowed whole and should not be chewed. For patients who are unable to swallow the capsule whole, CONSTELLA capsules can be opened and administered orally in applesauce or with water or administered with water via a nasogastric or gastric tube. Sprinkling of CONSTELLA beads on other soft foods or in other liquids has not been tested. For administration in applesauce: • Place one teaspoonful of applesauce at room temperature into a clean container. • Open the capsule. • Sprinkle entire contents (beads) on applesauce. • Consume the contents immediately. Do not chew the beads. Do not store the applesauce and beads for later use. For administration in water: • Pour approximately 30 mL of bottled water at room temperature into a clean cup. • Open the capsule. • Sprinkle entire contents (beads) into the water. • Gently swirl beads and water for at least 20 seconds. • Swallow the mixture of beads and water immediately. • Add another 30 mL of water to any beads remaining in the cup, swirl for 20 seconds and swallow immediately. • Do not store the bead-water mixture for future use. For nasogastric or gastric feeding tube administration in water: • Open the capsule and empty the beads into a clean container with 30 mL of room temperature bottled water. • Mix by gently swirling beads for at least 20 seconds. • Draw up the bead-water mixture into an appropriately sized catheter-tipped syringe and apply rapid and steady pressure (10 mL/10 seconds) to dispense the syringe contents into the tube. • Add another 30 mL of water to any beads remaining in the container and repeat the process. • After administering the bead-water mixture, flush the nasogastric/gastric tube with a minimum of 10 mL of water. • Use the mixture of beads and water immediately. Do not store for future use. Usual dose: IBS-C: Take 290 mcg orally once a day, at least 30 minutes before a meal. CIC: Take 145 mcg orally, once a day, at least 30 minutes before a meal. Your doctor may prescribe a dose of 72 mcg instead depending on your response. FC: Take 72 mcg orally, once a day, at least 30 minutes before a meal.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
CONSTELLA is contraindicated in: • pediatric patients under 6 years of age due to the risk of serious dehydration. • patients who are hypersensitive to linaclotide or to any ingredient in the formulation or component of the container. • patients with known or suspected mechanical gastrointestinal obstruction.
Warnings and precautions
CONSTELLA is contraindicated in children less than 6 years of age. In nonclinical studies in neonatal mice, administration of a single, clinically relevant oral dose of linaclotide caused deaths due to dehydration. Patients on treatment who experience severe diarrhea should stop CONSTELLA and contact their physician. In post-marketing experience, severe diarrhea associated with dizziness, syncope, hypotension and electrolyte abnormalities (hypokalemia and hyponatremia) requiring hospitalization or intravenous fluid administration have been reported in patients treated with CONSTELLA.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 3 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CONSTELLA | 290 MCG | CAPSULE | ABBVIE CORPORATION | MARKETED | 02417170 |
| CONSTELLA | 72 MCG | CAPSULE | ABBVIE CORPORATION | MARKETED | 02469510 |
2 · Same class — other molecules in ATC A06AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Prucalopride | APO-PRUCALOPRIDE · JAMP PRUCALOPRIDE · NRA-PRUCALOPRIDE · PMS-PRUCALOPRIDE · +2 more | 12 | 10 | Yes |
| Linaclotide | CONSTELLA | 3 | 3 | Yes |
| Plecanatide | TRULANCE | 1 | 1 | Yes |
| Glycerol | GLY-RECTAL SUP POUR ADULTES · GLYCERIN LIQ · GLYCERIN LIQUID · GLYCERIN SUPPOSITORIES · +7 more | 11 | 0 | Not in Canada |
| Other Laxatives | DYCHOLIUM TABLET 300MG | 1 | 0 | Not in Canada |
| Lubiprostone | AMITIZA | 1 | 0 | Not in Canada |
| Tenapanor | IBSRELA | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A06A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A06AB | Bisacodyl · Bisacodyl, Combinations · Cascara · Cascara, Combinations · Castor Oil · +9 more | 239 | 25 |
| A06AA | Docusate Sodium · Docusate Sodium, Combinations · Liquid Paraffin · Liquid Paraffin, Combinations | 144 | 22 |
| A06AD | Lactulose · Macrogol · Macrogol, Combinations · Magnesium Oxide · Magnesium Sulphate · +5 more | 86 | 21 |
| A06AH | Methylnaltrexone Bromide · Naloxegol | 5 | 3 |
| A06AG | Bisacodyl · Combinations · Docusate Sodium, Incl Combinations · Sodium Phosphate | 7 | 1 |
| A06AC | Ispaghula (Psylla Seeds) · Ispaghula, Combinations · Linseed · Methylcellulose · Polycarbophil Calcium · +2 more | 79 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is CONSTELLA called?
Also recorded in Canada as: linaclotide 0.145 MG Oral Capsule [Linzess] (US), linaclotide 0.29 MG Oral Capsule [Linzess] (US), linaclotide 0.072 MG Oral Capsule [Linzess] (US), linaclotide 0.145 MG Oral Capsule (US), linaclotide 0.29 MG Oral Capsule (US), linaclotide 0.072 MG Oral Capsule (US), LINACLOTIDE (US).
The same molecule, Linaclotide, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| LINZESS | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.